Nacuity and Arctic Therapeutics partner on NPI-001 for hereditary cystatin C amyloid angiopathy
Sep. 14, 2022
Nacuity Pharmaceuticals Inc. and Arctic Therapeutics LLC have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 (N-acetylcysteine amide, NACA) in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA).